I guess you missed my post yesterday https://in
Post# of 1418
(Total Views: 299)
Posted On: 03/19/2022 12:14:17 PM
Re: StoneBridge54 #619
I guess you missed my post yesterday
https://investorshangout.com/post/view?id=6365573
The 8% didn't save the deal. There was going to be a single digit royalty. How do I know, I read the PR last year. I mentioned before how bio deals are usually structured. Part cash, part funding and part royalty. Royalties are usually spoken as single or double digits. Single digits would have been 8-9%. I never see a low single digit.
So let's say NLC was going to get 8-9% of all revenue for ETERNATY. Baking that into the equity is a better deal for Todos and Todos shareholders for a number of reasons including, it makes the company easier to sell, makes it easier for Todos to buy the other 48%, etc. Also NCL has 8% more obligation in the long run. That 'obligation' is very important.
Dr Arad is great but just because you are great in one area doesn't make you an expert at everything. I doubt she's the 'Shark' you think she is and as an investor, I much prefer she focus on the science which btw, IS her role, than to also 'close deals' which are time consuming.
You can ask Gerald on twitter about the royalty is you have to know every little detail AFTER you read the entire filing and still have question. Oh, wait a second, on second thought, let the guy run the company for all of his shareholders. Is that you with the new handle on twitter?
Here's a link to the files. Let us know what you find about the deal.
https://www.sec.gov/Archives/edgar/data/16452...-index.htm
https://investorshangout.com/post/view?id=6365573
The 8% didn't save the deal. There was going to be a single digit royalty. How do I know, I read the PR last year. I mentioned before how bio deals are usually structured. Part cash, part funding and part royalty. Royalties are usually spoken as single or double digits. Single digits would have been 8-9%. I never see a low single digit.
So let's say NLC was going to get 8-9% of all revenue for ETERNATY. Baking that into the equity is a better deal for Todos and Todos shareholders for a number of reasons including, it makes the company easier to sell, makes it easier for Todos to buy the other 48%, etc. Also NCL has 8% more obligation in the long run. That 'obligation' is very important.
Dr Arad is great but just because you are great in one area doesn't make you an expert at everything. I doubt she's the 'Shark' you think she is and as an investor, I much prefer she focus on the science which btw, IS her role, than to also 'close deals' which are time consuming.
You can ask Gerald on twitter about the royalty is you have to know every little detail AFTER you read the entire filing and still have question. Oh, wait a second, on second thought, let the guy run the company for all of his shareholders. Is that you with the new handle on twitter?
Here's a link to the files. Let us know what you find about the deal.
https://www.sec.gov/Archives/edgar/data/16452...-index.htm
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼